Ishøy, Pelle L1; Knop, Filip K6; Broberg, Brian V7; Baandrup, Lone1; Fagerlund, Birgitte1; Jørgensen, Niklas R4; Andersen, Ulrik B3; Rostrup, Egill3; Glenthøj, Birte Y1; Ebdrup, Bjørn H1
1 Psykiatrisk Center Glostrup, Mental Health Services, The Capital Region of Denmark2 Department of Clinical Biochemistry, Amager and Hvidovre Hospital, The Capital Region of Denmark3 Klinik for Klinisk Fysiologi, Nuklearmedicin og PET, Diagnostisk Center, Rigshospitalet, The Capital Region of Denmark4 Klinisk Biokemisk Afdeling, Diagnostisk Center, Rigshospitalet, The Capital Region of Denmark5 Clinical Intervention and Neuropsychiatric Schizophrenia Research/Center for Neuropsykiatrisk Skizofreniforskning, Psykiatrisk Center Glostrup, Mental Health Services, The Capital Region of Denmark6 Center for Diabetesforskning, Internal Medicine, Gentofte, Herlev and Gentofte Hospital, The Capital Region of Denmark7 Danish Research Centre for Magnetic Resonance, Centre for Functional and Diagnostic Imaging and research, Amager and Hvidovre Hospital, The Capital Region of Denmark
the TAO study protocol
Antipsychotic medication is widely associated with dysmetabolism including obesity and type 2 diabetes, cardiovascular-related diseases and early death. Obesity is considered the single most important risk factor for cardiovascular morbidity and mortality. Interventions against antipsychotic-associated obesity are limited and insufficient. Glucagon-like peptide-1 (GLP-1) receptor agonists are approved for the treatment of type 2 diabetes, but their bodyweight-lowering effects have also been recognised in patients with non-diabetes. The primary endpoint of this trial is weight loss after 3 months of treatment with a GLP-1 receptor agonist (exenatide once weekly) in patients with non-diabetic schizophrenia with antipsychotic-associated obesity. Secondary endpoints include physiological and metabolic measurements, various psychopathological and cognitive measures, and structural and functional brain MRI.